entity

TFR1, LRP1, CAV1, ABCB1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TFR1, LRP1, CAV1, ABCB1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

13Connections
1Hypotheses
1Analyses
2Outgoing
11Incoming
8Experiments
1Debates

No AI portrait yet

Wiki Pages (20)

Knowledge base pages for this entity

cbs-psp-daily-action-plan

therapeutic · 30834 words

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

therapeutic · 15794 words

Blood-Brain Barrier Dysfunction in Neurodegeneration

mechanism · 4726 words

Blood-Brain Barrier Biology and Crossing Strategies

mechanism · 4474 words

Exosome and Extracellular Vesicle Brain Delivery

therapeutic · 3732 words

Outgoing (2)

TargetRelationTypeStr
neurodegenerationassociated_withdisease0.50
benchmark_ot_ad_answer_key:TFR1, LRP1, CAV1, ABCB1data_indataset_row0.00

Incoming (11)

SourceRelationTypeStr
LRP1, MTNR1A, MTNR1Bdebate_co_mentiongene0.45
MTNR1Adebate_co_mentiongene0.45
OCLNdebate_co_mentiongene0.45
TFR1debate_co_mentiongene0.45
AQP4co_associated_withgene0.40

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Synthetic Biology BBB Endothelial Cell Reprogramming 0.727 neurodegeneration Blood-brain barrier transport mechanisms

Mentioning Analyses (1)

Scientific analyses that reference this entity

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.773

Experiments (8)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
Vascular Contribution to Alzheimer's Disease — Beyond Amyloid validation Alzheimer's Disease 0.400 0.50 human proposed $2,280,000
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy validation Parkinson's Disease 0.400 0.50 mouse proposed $280,000
AAV Serotype Comparison for LRRK2 Knockdown in PD validation Parkinson's Disease 0.400 0.50 mouse proposed $280,000
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown validation Parkinson's Disease 0.400 0.50 mouse proposed $280,000
Blood-Based Biomarker Panel for Early AD Detection clinical Alzheimer's Disease 0.400 0.50 cell_line proposed $220,000
Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neur validation Neurodegeneration 0.400 0.50 cell_line proposed $130,000
s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin falsification Neuroinflammation 0.400 0.50 mouse proposed $200,000
s:** - Compare uptake with/without magnetic particles using tight junc falsification Neurodegeneration 0.400 0.50 cell_line proposed $120,000

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (1)

Multi-agent debates referencing this entity

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

closed · Rounds: 4 · Score: 0.91 · 2026-04-06